Subtype Specific Elevated Expression of Hyaluronidase-1 (HYAL-1) in Epithelial Ovarian Cancer by Yoffou, Paule Héléna et al.
Subtype Specific Elevated Expression of Hyaluronidase-1
(HYAL-1) in Epithelial Ovarian Cancer
Paule He ´le ´na Yoffou
1, Lydia Edjekouane
1, Liliane Meunier
5, Andre ´ Tremblay
3,4,6, Diane Miche `le
Provencher
3,5, Anne-Marie Mes-Masson
2,3,5, Euridice Carmona
1,2*
1Maisonneuve-Rosemont Hospital Research Center, Montreal, Quebec, Canada, 2Department of Medicine, University of Montreal, Montreal, Quebec, Canada,
3Department of Obstetrics and Gynecology, University of Montreal, Montreal, Quebec, Canada, 4Department of Biochemistry, University of Montreal, Montreal, Quebec,
Canada, 5Centre de recherche du Centre hospitalier de l’Universite ´ de Montre ´al/Institut du cancer de Montre ´al, Montreal, Quebec, Canada, 6Research Center, Centre
hospitalier universitaire Ste-Justine, Montreal, Quebec, Canada
Abstract
Background: Epithelial ovarian cancer (EOC) is morphologically heterogeneous being classified as serous, endometrioid,
clear cell, or mucinous. Molecular genetic analysis has suggested a role for tumor suppressor genes located at chromosome
3p in serous EOC pathogenesis. Our objective was to evaluate the expression of HYAL1, located at chromosome 3p21.3, in
these EOC subtypes, and to investigate its correlation with the expression of steroid hormone receptors.
Methodology/Principal Findings: We determined the mRNA expression of HYAL1, estrogen receptor (ER)-a,E R b and
progesterone receptor (PR) in EOC tumor samples and cell lines using quantitative RT-PCR. We also examined the expression
of these genes in a publicly available microarray dataset. HYAL-1 enzyme activity was measured in EOC cell lines and in
plasma samples from patients. We found that HYAL1 mRNA expression was elevated in clear cell and mucinous EOC tissue
samples, but not in serous and endometrioid samples, normal ovaries or benign tumors. Similar results were obtained by
two different techniques and with tissue sample cohorts from two independent institutions. Concordantly, HYAL1 mRNA
levels and enzymatic activity were elevated only in EOC cell lines derived from clear cell and mucinous subtypes. We also
showed that HYAL1 mRNA was inversely correlated to that of ERa specifically in clear cell and mucinous EOCs. Additionally,
ectopic expression of ERa in a clear cell EOC cell line (ER- and PR-negative) induced 50% reduction of HYAL1 mRNA
expression, supporting a role of ERa in HYAL1 gene regulation. Significantly, HYAL-1 activity was also high in the plasma of
patients with these EOC subtypes.
Conclusions/Significance: This is the first report showing high HYAL-1 levels in EOC and demonstrating HYAL1 gene
repression by ERa. Our results identify Hyaluronidase-1 as a potential target/biomarker for clear cell and mucinous EOCs and
especially in tumors with low ERa levels.
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Introduction
Epithelial ovarian cancer (EOC) is the leading cause of death
from gynecologic cancer in most Western countries [1]. Because of
its asymptomatic growth and the lack of effective screening
methods, about 70% of all cases are diagnosed in an advanced
stage, with only modest improvements in survival over the past 40
years [1]. Although most patients respond to chemotherapy
initially, recurrence rates are very high resulting in the general
poor prognosis seen in these patients [2]. Furthermore, EOCs are
morphologically heterogeneous, and different histopathological
subtypes have distinct molecular characteristics and diverse
response to treatment [3]. EOC can be classified as serous,
endometrioid, clear cell or mucinous which correspond to the
different types of epithelia present in the female reproductive tract
[4]. Differences in chemotherapy response and patient outcomes
probably result from the molecular heterogeneity of these
morphologically distinct EOCs [3]. For instance, TP53 mutations
are frequently observed in serous and endometrioid cancers, but
are scarcely detected in clear cell and mucinous EOCs [3]. It is
also known that the frequency of chromosomal instability is higher
in serous EOC than in the other subtypes [3].
In serous EOC, molecular genetic analysis has suggested a role
for tumor suppressor genes located on the short arm of
chromosome 3 (3p) in the pathogenesis of this disease [5].
Transcriptome analysis of chromosome 3 genes identified several
differentially expressed genes in EOC cell lines and ovarian tumors
when compared to normal ovarian surface epithelial (NOSE) cells
[6,7]. Chromosomal aberrations in 3p21.3 are frequently found in
lung, renal and breast cancers, suggesting that they harbor tumor
suppressor genes [8]. Located on chromosome 3p21.3 is a cluster
of genes, named hyaluronidases (HYAL1, HYAL2 and HYAL3), that
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10are the most frequent target of homozygous deletions in lung
cancer [8].
Mammalian hyaluronidases (EC 3.2.1.35) are endo-N-acetyl-
hexosaminidases which hydrolyze the glycosaminoglycan hyalur-
onan. They comprise a family of 6–7 genes with approximately
40% identity among each other [9,10]. In humans, they are
clustered in groups of three on chromosomes 3p21.3 (HYAL1,
HYAL2 and HYAL3) and 7q31.3 (HYAL4, PH20/SPAM1 and
HYALP1), with HYALP1 being a pseudogene and HYAL4 coding
for a chondroitinase enzyme [9,11]. Therefore, in humans, there
are four hyaluronidases, HYAL-1, -2, -3 and PH20/Spam1, the
latter being mainly expressed in the male reproductive tract and
having an important role in fertilization [12]. On the other hand,
hyaluronidases located on chromosome 3 are ubiquitously
expressed. HYAL-1 and HYAL-2 are the main somatic hyaluron-
idases responsible for hyaluronan turnover and are known to have
several physiological and pathological roles [9,13], such as wound
healing, inflammation and osteoarthritis. In contrast, Hyal-3 has
been described to be devoid of hyaluronan enzymatic activity [14]
and its physiological role still remains to be determined.
In ovarian cancer, allelic imbalance of these three genes
(HYAL1, HYAL2 and HYAL3) has been shown in tumor and
stroma tissues [15]. In particular, HYAL-1 mRNA expression was
found to be significantly reduced in serous EOC when compared
to normal ovaries [16], while unchanged or a tendency for
decreased HYAL-1 activity was reported in EOC tissue extracts
[16,17]. In accordance with this observation, extracellular
accumulation of hyaluronan is often observed in ovarian tumor
stroma and pericellular matrix, and is associated with poor disease
outcome [17,18]. In addition, several reports have demonstrated
interactions between hyaluronan and membrane receptors, such
as CD44, which promotes the association of CD44 with certain
cytoskeletal proteins (e.g. ankyrin, RhoGTPases, Cdc42) generat-
ing specific signalling events promoting ovarian cancer cell
adhesion, migration and survival [19].
In contrast, levels of both hyaluronan and HYAL-1 have been
reported to be increased in bladder, prostate and head and neck
cancers, and to be implicated in tumor progression and metastasis
[20–22]. Interestingly, elevated extracellular hyaluronan is mainly
found in tumor stroma while elevated HYAL-1 levels are detected
in tumor tissues, suggesting a cross-talk between these two tissue
types. High levels of HYAL-1 expression are also found in breast
cancer and glioblastomas, and are correlated with metastatic
tumors [22,23]. Interestingly, estrogen receptor (ER) negative
breast cancer cell lines, which tend to be more aggressive, have
enhanced hyaluronidase activity when compared to ER positive
cell lines [24]. By a mechanism yet unknown, HYAL-1 induces cell
cycle transition and up-regulates the levels of positive regulators of
G2-M transition (e.g. cdc25c, cyclin B1, cdk10) in bladder,
prostate and oral squamous cancer cell lines [25–27]. HYAL-1
also enhances angiogenesis, probably by generating hyaluronan
fragments of distinct sizes which possess the ability to stimulate
endothelial cell proliferation and capillary formation [28].
Therefore, levels of hyaluronidase expression may vary
depending on tumor type and on its aggressive behaviour. In the
present work we performed a detailed study on the expression of
HYAL-1 in ovarian cancer tissue samples representing four
different histopathological subtypes and showed elevated levels of
this enzyme in clear cell and mucinous EOCs, but not in serous or
endometrioid. We also demonstrated that levels of HYAL1 mRNA
in clear cell and mucinous EOCs were inversely correlated with
those of ERa. Significantly, we showed that ectopic expression of
ERa induced a 50% decrease in HYAL1 mRNA expression in a
clear cell EOC cell line. To our knowledge, this is the first report:
i) demonstrating increased HYAL-1 expression in specific mor-
phological EOC subtypes, ii) showing an inverse correlation
between HYAL1 and steroid hormones in tissue samples, and iii)
implicating HYAL1 gene as an ERa target for gene repression.
Finally, we showed a 2.1–2.8 fold increase in the plasma levels of
this enzyme in patients with clear cell and mucinous EOC, but not
in those with serous or endometrioid tumors, when compared to
patients with benign cysts. Our present results identify HYAL-1 as
a potential biomarker for the detection of these two distinct EOC
subtypes.
Materials and Methods
Clinical samples
Tissue tumor samples and EDTA-collected plasma were
obtained, with informed consent, from participants undergoing
surgeries performed at the Centre hospitalier de l’Universite ´d e
Montre ´al (CHUM) Ho ˆpital Notre-Dame. The policies for
collection and use of tissue and blood samples were approved
by the Research Ethics Committee of the CHUM. Only tumors
from chemotherapy naı ¨ve patients were used. Histopathology,
grade and stage of tumors were assigned according to the
International Federation of Gynecology and Obstetrics (FIGO)
criteria. As normal ovary has little epithelial content, benign
serous ovarian tumors were used as a control. Information
concerning the samples used in the present study is summarized
in Table 1.
Cell Lines
Primary cultures of normal ovarian surface epithelium (NOSE)
cells were derived, as previously described [29], from ovaries of
three participants with no prior history of ovarian cancer, following
profilactic oophorectomy at the CHUM Ho ˆpital Notre-Dame and
informed consent. EOC cell lines were established as previously
described [29–31], and were derived from serous epithelial ovarian
tumors (TOV81D, TOV2223, TOV1946) or ascites fluid
(OV1946, OV866), from an endometrioid ovarian tumor
(TOV112D), a clear cell carcinoma (TOV21G), and a mucinous
epithelial ovarian cancer (TOV2444). Cells were cultured in OSE
medium (Wisent Inc., St-Bruno, QC, Canada) containing 2.5 mg/
ml amphotericin B and 50 mg/ml gentamicin (both from Invitro-
gen, Burlington, ON, Canada). Culture media was supplemented
with 15% fetal bovine serum (FBS, Invitrogen) for the NOSE
cultures and 10% FBS for the EOC cell lines.
Quantitative real-time RT-PCR (Q-PCR)
Total RNA was extracted with Trizol reagent (Invitrogen) from
frozen tumor samples or directly from cells grown to 80%
confluency as described previously [32]. RNA quality was routinely
monitored by agarose gel electrophoresis and with the 2100
Bioanalyzer, using the RNA 6000 Nano LabChip kit (Agilent
Technologies, Waldbronn, Germany). The cDNA synthesis was
performed according to the protocol of the QuantiTect Reverse
Transcription kit (Qiagen Inc., Mississauga, ON, Canada) using
1 mg of total RNA. The obtained cDNA solution was diluted ten
times and 5 ml aliquots were used in each Q-PCR reaction.
Quantitative amplifications were obtained using the PlatinumH
SYBRH Green Q-PCR supermix UDG (Invitrogen) and the
following pair of primers: 59-AAGCCCTCCTCCTCCTTAAC-
C-39 and 59-AGCCAGGGTAGCATCGAC-39 for HYAL1,5 9-
CGCGCTCTACCCTGCACTC-39 and 59-TGAATCCGGCCT-
CAGGTAGTT-39 for ERa,5 9-TGGGCTTACTGACCAACC-
TG-39 and 59-CCTGATCATGGAGGGTCAAA-39 for ERb,5 9-
AGAGTCCCTGGTGTGAAGCAA-39 and 59-GACAGCGCA-
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TGGCTCACCCCTACCT-39 and 59-GCCCCAGGGTGCAG-
AGATGTC-39forERK1.TheabovementionedERa,ER b andPR
primer sequences were obtained from a previous publication [33].
ERK1 was chosen as the control gene based on its stable expression
in ovarian samples, consisting of normal and different EOC
subtypes [34,35], and as previously described [34]. Fluorescence
was captured using the iCycler iQ real-time detection system
(BioRad Laboratories, Hercules, CA). Amplifications were carried
out at 50uC for 2 minutes (UDG incubation), 95uC for 3 minutes
(denaturing), and 50 cycles of 95uC/30 sec, 58uC/30 sec and
72uC/45 sec, followed by a melting curve of 70 cycles of 0.5uC
increase/cycle starting at 60uC. Positive and negative controls were
introduced in all experiments, and purity and specificity of the PCR
products were sporadically monitored by agarose gel electrophore-
sis. PCR reactions were performed at least three times for each
cDNA sample in separate experiments. Relative expression value
was obtained by the 1/2
DCt method using ERK1 as the controlgene.
In this method, the difference in CT (DCT) between the target and
the control genes was used to determine gene expression with the
formula 2
DCT. A normalized value of expression for the target gene
with reference to the control gene was then obtained by the
calculation 1/2
DCT. All mRNA expression values were ratios
relative to the control ERK1 gene.
To monitor the biological response of ERa ectopic expression
on TOV21G cells (see below), Q-PCR was performed to measure
mRNA levels of known ERa targets, e.g. GREB1 (growth
regulation by estrogen in breast cancer 1) and TFF1 (trefoil factor
1, also known as pS2 gene) [36,37]. PCR reactions were
performed as above described using the following pairs of primers:
59-TTCCCCGAAGTGCCAACAAC-39 and 59-ATGGAGATT-
CTGGAGACCACCC-39 for GREB1, and 59-TGGAGAACAA-
GGTGATCTGCG-39 and 59-CGAAACAGCAGCCCTTATT-
TGC-39 for TFF1.
GEO Dataset Analysis
Gene expression profiles of several tissue samples of the four
morphologically distinct ovarian cancers and of normal ovaries has
been performed using the Affymetrix HG_U133A array [35] and
was made accessible through the National Center for Biotechnology
Information (NCBI) (GEO dataset GSE6008). In the present study,
we uploaded the raw table for each tumor sample and selected the
normalized values [quantile-normalized trimmed-mean, log-trans-
formed with log(max(x+50,0)+50] for the hybridization of
the probes of interest. In the case of HYAL1 and PR, the
Affymetrix HG_U133A array contained only one probe for each
of these genes (210619_s_at and 208305_at, respectively).
Therefore, these values were used as such in our analysis to
evaluate the expression of these genes in individual tissue
samples. However, for ERa and ERb several probes were
available (205225_at, 211233_x_at, 211234_x_at, 211235_s_at,
211627_x_at, 215551_at, 215552_s_at, 217163_at, 217190_x_at
for ERa; and 210780_at, 211117_x_at, 211118_x_at, 211119_at,
211120_x_at forERb), and the averageof the normalized values for
the probes of each gene was used in our work to analyse the
expression of these genes in individual tissue samples. Information
concerninghistology, grade and stage of these samples was obtained
from the available supplemental material [35] and is summarized in
Table 1.
Hyaluronan zymography
To monitor hyaluronidase activity of cell lysates from ovarian
cancer cell lines, hyaluronan zymography was performed as
previously described [38]. Cells harvested from 80% confluent
Table 1. Samples and clinical data of ovarian cancer patients for each analysis dataset.
Dataset Samples G1 G2 G3
Stage 1–2 3–4 n.a 1–2 3–4 n.a 1–2 3–4 n.a
Q-PCR
(n=53)
Benign (n=15) :
serous-subtype (14)
mucinous-subtype (1)
Serous (n=10) 2
20%
2
20%
2
20%
4
40%
Endometrioid (n=9) 1
11%
1
11%
1
11%
1
11%
1
11%
4
44%
Clear cell (n=11) 1
9%
1
9%
2
18%
5
45%
1
9%
Mucinous (n=6) 3
50%
1
17%
1
17%
1
17%
Micro-array
(a)
(n=99)
Normal (n=4)
Serous (n=41) 1
2%
4
10%
3
7%
10
24%
4
10%
19
46%
Endometrioid (n=37) 10
27%
1
3%
10
27%
3
8%
3
8%
10
27%
Clear cell (n=8) 6
75%
2
25%
Mucinous (n=13) 8
61%
1
8%
1
8%
1
8%
1
8%
1
8%
For each category of grade and stage, top number (bold font) corresponds to number of patients and bottom number to their corresponding percentage value.
(a)From publicly available dataset [35].
n.a – denotes not available.
doi:10.1371/journal.pone.0020705.t001
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0.25 M sucrose), briefly sonicated and their protein content
determined by the BioRad Protein Reagent. Samples (containing
30 mg of protein) were separated by native PAGE (20 mA, 4uC) on
an 8% gel containing 0.25 mg/ml human umbilical cord
hyaluronic acid (Sigma-Aldrich, Oakville, Ontario, Canada).
The gel was then briefly equilibrated in the assay buffer specific
for hyaluronidase-1 detection (100 mM sodium formate, 150 mM
NaCl, pH 3.7) and subsequently incubated overnight in the same
buffer at 37uC. After incubation, gels were treated with 0.01 mg/
ml Pronase (Sigma-Aldrich) in a 20 mM Tris buffer (pH 8.0) for
4 h, rinsed with distilled water, and stained sequentially with 0.5%
Alcian blue and 0.1% Coomassie blue R, both in 30%
methanol:10% acetic acid. Gels were de-stained until clearing
bands of digested hyaluronan were evident. Gel zymography was
repeated three times for each cell line using cell extracts from
different cultures.
HYAL-1 enzymatic activity of plasma samples
Quantification of HYAL-1 activity in plasma sample was
assayed by a colorimetric method for the estimation of N-Acetyl-
D-glucosamine (NADG) released after hyaluronan digestion
[39,40]. Briefly, aliquots of EDTA-treated plasma (around 4 ml,
containing 30 mg proteins, as determined by the BioRad Protein
Reagent) were incubated with 40 mg of hyaluronan from human
umbilical cord (Sigma-Aldrich) in 200 ml final volume of reaction
buffer (79 mM sodium formate, 150 mM NaCl, 0.2 mg/ml BSA,
pH 3.9) at 37uC for 24 h. The reaction was terminated by
addition of 40 ml of 1.2 M potassium tetraborate pH 9.1 and
boiled for 3 min. Colour formation is revealed by the addition of
1.2 ml of p-dimethylaminobenzaldehyde reagent (prepared as
previously described [39,40]) and incubation at 37uC for 20 min
in the acidic environment of this reagent. Samples were
immediately read at 585 nm. Hyaluronidase activity was
estimated from a NADG (Sigma-Aldrich) standard curve (1 to
10 nmols), and was expressed as nmol/mg protein. Plasma
protein content was determined by the BioRad Protein Assay.
Blanks were obtained by omitting the plasma samples. Each
plasma sample was measured at least three times in separate
experiments.
TOV21G cell transfection
pCDNA plasmid (Invitrogen) containing the human estrogen
receptor alpha sequence (named pERa) has been described
[41,42]. TOV21G cells were cultured in complete OSE (Wisent)
medium as described above until cells were around 60% confluent.
Cells were transiently transfected with 1 mg pERa in DMEM-F12
medium (Wisent) without supplements using the GeneJuice
transfection reagent (EMD Chemicals, Gibbstown, NJ), according
to the manufacturer’s instruction. After an overnight transfection,
the medium was replaced by complete OSE medium, and cells
were cultured for an extra 24 h for protein expression. At the end
of the experiment, cells were harvested by trypsin-EDTA
treatment (0.25% trypsin with 1 mm EDTA; Invitrogen), washed
in PBS and used for RNA extraction and Q-PCR or for protein
extraction and immunoblotting. Transfection experiments were
repeated at least three times.
Immunoblotting
Cells were lysed in Tris-buffered saline (20 mM Tris-HCl,
150 mm NaCl, pH 7.4)(TBS) containing 0.1% Triton X-100,
1 mM orthovanadate, 1 mM NaF, 0.1 mM PMSF and 16
protease inhibitor cocktail (Complete-mini, Roche Diagnostics
Canada, Laval, QC, Canada). Protein content was determined by
the BioRad Protein Reagent using a BSA standard curve. Samples
(lysates of approximately 30 mg protein) were subjected to 12%
SDS-PAGE, under reducing conditions, and electrotransferred
onto nitrocellulose membranes. Non-specific binding to the
membrane was blocked with 5% dehydrated skim milk in TBS.
Membranes were then incubated with primary antibodies (4uC,
overnight), washed in TBS containing 0.1% Tween, and
incubated with horseradish peroxidase conjugated secondary
antibodies. The primary IgG antibodies used in our work were
anti-ERa (H-184, 1:1000, rabbit antibody; Santa Cruz Biotech-
nology, Santa Cruz, CA) and anti-actin (pan Ab-5, 1:1500, mouse
antibody; Lab Vision Corp., Fremont, CA). These antibodies were
tested in our conditions to be specific for their target proteins.
Peroxidase-conjugated anti-mouse IgG (1:1000, goat antibody;
Sigma) and anti-rabbit IgG (1:3000, goat antibody; Bio-Rad) were
used as secondary antibodies. Protein-antibody recognition was
detected by Western Lightning Chemiluminescence Reagent Plus
(PerkinElmer, Boston, MA), according to the manufacturer’s
instructions.
Statistical analysis
Because the levels of HYAL-1 and hormone receptors were not
always normally distributed, nonparametric tests were used to
analyse gene expression in tissue samples and enzymatic activity in
plasma samples. We first performed a nonparametric Kruskal-
Wallis analysis of variance and when significant differences were
observed, we conducted Mann Whitney tests comparing the group
of normal (for microarray) or benign (for Q-PCR and activity)
samples with each of the tumor subtypes separately. Statistical
significance was considered at P,0.05. Spearman’s rank correla-
tion coefficients were calculated and were considered statistically
significant when P,0.05. Differences in gene expression of
transfected and non-transfected TOV21G cells were analysed by
the Student’s t-test (two-tailed, equal-variance) and were consid-
ered significant when P,0.05. All statistical analyses were done
using Prism4 for Windows version 4 (GraphPad Software, Inc.).
Results
Hyaluronidase-1 expression is elevated in clear cell and
mucinous but not in serous and endometrioid EOC
In the past, the expression of Hyaluronidase-1 in ovarian cancer
has been described specifically in serous tumors [16,17], most
probably because this is the most frequent EOC subtype [4]. In
the present study we analysed the mRNA expression of this
enzyme by Q-PCR in ovarian cancer tissue samples obtained from
patients with different morphological subtypes of this disease, e.g.
serous (11 samples), endometrioid (9 samples), clear cell (11
samples) and mucinous (8 samples). Expression levels were then
compared to those of 15 benign ovarian tumors. Benign tumors
were chosen for comparison due to their abundant content of
surface epithelium which is very few in normal ovaries. In
addition, we wanted to avoid possible interference of HYAL-1
expression in other ovarian cell types. For instance, we have shown
that this enzyme is expressed in mouse ovarian granulosa cells
[38]. As shown in Figure 1A, levels of HYAL1 mRNA are
significantly elevated in clear cell and mucinous carcinomas (Mann
Whitney test, P,0.05) but not in serous and endometrioid tumors.
Because the size of our sample cohort could be considered small,
we decided to validate our results by analysing HYAL1 mRNA
expression in a publicly available microarray dataset [35] (GEO
dataset GSE6008) containing 41 serous, 37 endometrioid, 8 clear cell
and13mucinousEOCsamples,and4normalovariantissuesamples.
Figure 1B shows the normalized values [quantile-normalized
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hybridization of each sample with the HYAL1 probe (210619_s_at) of
the Affymetrix HG_U133A array. Consistent with our Q-PCR
results, no significant difference was observed for HYAL1 mRNA
expression between normal ovarian tissues and that of serous or
endometrioid tumorsamples(Figure1B). Clearcellcarcinomashad a
tendency to express higher levels of HYAL1 mRNA than normal
ovarian tissue but no statistical significance was attained. In
accordance to our results, mucinous samples had statistically
significant higher levels of HYAL1 than normal tissue (Mann Whitney
test, P,0.05) (Figure 1B).
Ovarian cancer cell lines derived from tumor samples of these
different morphological subtypes have been previously character-
ized and showed behaviour similar to the tumor sample from
which they originated [29–31]. They provide powerful tools to
investigate the molecular events related to each morphologically
Figure 1. HYAL-1 expression in ovarian cancer tissue samples and cell lines. A) Q-PCR for HYAL1 mRNA expression in benign tumor (white
bar), and in serous (dotted bar), endometrioid (hatched bar), clear cell (shaded bar) and mucinous (black bar) EOC tissue samples from patients. Bars
represent the mean 6 SEM of the relative HYAL1 expression normalized to control gene ERK1 from different patients in each group. The value for
each individual cDNA sample is the mean of 3–4 separate Q-PCR measurements. * denotes P,0.05 on Mann Whitney test. B) Normalized values for
HYAL1 probe hybridization of the Affymetrix HG_U133A array (GEO dataset GSE6008) on RNA samples of normal ovarian tissues (white bar), and of
serous (dotted bar), endometrioid (hatched bar), clear cell (shaded bar) and mucinous (black bar) EOCs. Bars represent the mean 6 SEM of raw values
of normalized HYAL1 hybridization. * denotes P,0.05 on Mann Whitney test. C) Q-PCR for HYAL1 mRNA expression in cell lines derived from normal
ovarian epithelium (NOV2667D, NOV2809D, NOV2206D; white bars), and from serous (TOV81D, TOV2223, TOV1946, OV1946, OV866; dotted bars),
endometrioid (TOV112D; hatched bar), clear cell (TOV21G; shaded bar) and mucinous (TOV2444; black bar) EOCs. Bars represent the mean of the
relative HYAL1 expression normalized to control gene ERK1 for each cell line. Q-PCR measurements were repeated at least three times for each cell
line cDNA. Cell lines derived from different EOC subtypes are represented in separate bars therefore no error bars are represented. Vertical arrows
indicate clear cell and mucinous cell lines having high HYAL1 mRNA expression. D) Hyaluronan zymogram of cell lysates from the above mentioned
serous, endometrioid, clear cell and mucinous ovarian cancer cell lines. The horizontal arrow marks the clear band of digested hyaluronan. The image
is representative of three independent zymogram experiments.
doi:10.1371/journal.pone.0020705.g001
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level of expression of HYAL1 mRNA and protein in these cell lines.
Primary cell cultures of normal ovarian surface epithelium (NOSE)
[29] were used as controls. Figure 1C shows that, as expected,
mRNA expression of HYAL1 were particularly high in cell lines
TOV21G (derived from a clear cell carcinoma) and TOV2444
(derived from a mucinous EOC). An intermediate level of HYAL1
mRNA expression was observed in the cell line TOV112D, which
was derived from an endometrioid ovarian tumor. Cell lines
derived from serous epithelial ovarian cancer at the primary site
(TOV81D, TOV2223, TOV1946) or from the ascites fluid
(OV1946, OV866) showed low levels of HYAL1 expression,
comparable to those of NOSE cell lines. In order to demonstrate
that mRNA expression levels, measured quantitatively by our set
of primers, reflected the amount of HYAL-1 protein in these
samples, we measured HYAL-1 enzymatic activity by a substrate-
gel zymogram. This is a conventional method to measure
hyaluronidase activity and is specific for Hyaluronidase-1 when
assayed at acidic pH [38]. Figure 1D shows a clear band of
digested substrate (hyaluronan) only in the cell lysates of TOV21G
and TOV2444 cell lines. The HYAL-1 enzymatic activity in the
serous and endometrioid samples was below the detection level of
our assay.
Because elevated HYAL-1 levels have been previously corre-
lated with higher grade bladder and prostate tumors [21,22], we
decided to verify whether levels of HYAL1 mRNA in clear cell and
mucinous ovarian tumors would correlate with disease grade or
stage (see Table 1 for patients’ information). However, Spearman
correlation analyses did not reveal a significant positive correlation
between levels of HYAL1 mRNA and either grade or stage in clear
cell (r=0.262 and 20.322 for grade and stage respectively in our
data set, and r=0.055 for stage in the microarray data, all
P.0.05) or mucinous tumor samples (r=20.655 and 20.577 for
grade and stage respectively in our data set, and r=20.094 and
20.378 for grade and stage in the microarray data, all P.0.05).
Global analysis including all subtypes did not show a significant
positive correlation either (r=20.234 and 20.251 for grade and
stage respectively in our data set, and r=0.185 and 0.042 for
grade and stage in the microarray data, all P.0.05). These results
suggest that HYAL-1 expression might be an intrinsic phenotypic
characteristic of clear cell and mucinous EOCs and that it might
be used as diagnostic/detection marker for these ovarian cancer
subtypes.
Hyaluronidase-1 activity can be detected in the
conditioned culture medium of TOV21G cell line and is a
potential serum/plasma biomarker for clear cell and
mucinous EOC
It has been shown that HYAL-1 is present in the culture
medium of prostate and bladder cancer cell lines as well as in the
urine of patients with bladder cancer [21,26,27]. In the present
work, we wanted to verify whether HYAL-1 was also secreted by
EOC cell lines and whether it could be used as a serum/plasma
marker for the two morphological subtypes in which its expression
level is elevated, e.g. clear cell and mucinous EOC. Figure 2A
shows the presence of HYAL-1 activity (clear band of digested
hyaluronan) in the concentrated serum-free conditioned medium
of TOV21G cell culture as well as in its cell lysate. In contrast, no
enzymatic activity can be detected in concentrated conditioned
medium and cell lysate from the TOV1946 cell line (derived from
a serous EOC). Having established that HYAL-1 is secreted by
ovarian cancer cells expressing this enzyme, we investigated
whether this enzymatic activity could be differentially detected in
Figure 2. Secreted HYAL-1 protein as a potential plasma
biomarker for the identification of clear cell and mucinous
EOC. A) Hyaluronan zymogram of cell lysates (lanes 1, 4 and 5) and
concentrated conditioned culture media (lanes 2 and 3) from serous
(TOV1946) and clear cell (TOV21G) ovarian cancer cell lines. Note the
clear band of digested hyaluronan specifically with the TOV21G
samples. The image is representative of three independent exper-
iments. B) HYAL-1 enzymatic activity of plasma samples were assayed
quantitatively by a modified Reissig method [39,40]. Bars represent the
mean 6 SEM of HYAL-1 activity measured in plasma samples of patients
with benign ovarian tumor (white bar), or with serous (dotted bar),
endometrioid (hatched bar), clear cell (shaded bar) or mucinous (black
bar) EOCs. The value for each plasma sample is the mean of 3–4
measurements performed independently. * denotes P,0.05 on Mann
Whitney test. C) Correlation graph of HYAL-1 enzymatic activity in
plasma samples with HYAL1 mRNA expression in tissue samples from
patients with serous (white circles), endometrioid (black triangles), clear
cell (black squares) and mucinous (white inverted triangles) EOCs. Each
point represents the correlation value for one patient. Significance
(P,0.01) was analysed by the Spearman correlation coefficient.
doi:10.1371/journal.pone.0020705.g002
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Because HYAL-1 has long been known to be present in
mammalian serum/plasma [43,44], a method other than the
gel-substrate zymogram is needed to better determine differences
in plasma/serum levels of this enzyme. For this purpose, we used a
quantitative method for HYAL-1 activity measurement in solution
[39], which has been recently used to detect the activity of this
enzyme in human serum and plasma [40]. The activity of HYAL-
1 was assayed in the plasma of patients with serous (10 samples),
endometrioid (11 samples), clear cell (13 samples) or mucinous (10
samples) EOC, and compared to activities in plasma from 14
patients having benign ovarian tumors. As expected, HYAL-1
enzyme activity was detected in all plasma samples (Figure 2B).
However, levels of this enzyme were significantly higher in plasma
samples from patients with clear cell (0.039660.0131 nmol/mg,
P,0.0001) and mucinous (0.030260.0107 nmol/mg, P,0.005)
EOC than those of patients with benign tumors (0.01446
0.0032 nmol/mg) (2.8 and 2.1 fold increase respectively). HYAL-
1 levels in plasma from patients having serous or endometrioid
EOC (0.014060.0036 and 0.015760.0025 nmol/mg respectively)
were similar to those of benign.
For some EOC patients we had paired analysis of HYAL1
Q-PCR from tissue samples and HYAL-1 activity from plasma
samples. Importantly, Spearman correlation analysis revealed a
significant correlation between levels of this enzyme in tumor
tissue and circulating plasma (Figure 2C, r=0.706, P,0.001),
reinforcing our assumption that this enzyme can be potentially
used as a biomarker for the detection of clear cell and mucinous
EOCs.
Expression of HYAL1 in clear cell and mucinous EOC
inversely correlates with those of ERa and PR
Although the etiology of ovarian cancer is not clear,
reproductive factors have been consistently recognized as risk
factors. For instance, age at menopause and infertility contribute
to a greater risk of ovarian cancer, whereas previous pregnancy,
tubal ligation, and hysterectomy reduce risk. Oral contraceptive
use has clearly been shown to be protective against ovarian cancer
[45,46]. In contrast, large epidemiologic studies found menopausal
hormone replacement therapy to be a significant risk factor
[47,48]. Accordingly, and similarly to breast cancer, reports have
shown that low ER and PR levels in ovarian cancers are associated
with reduced survival and poor prognosis [49–53]. Interestingly,
hyaluronidase activity has been shown to be elevated in
ER-negative breast cancer cell lines [24]. Therefore in the present
study we analysed the mRNA expression levels of ERa,E R b and
PR in the above mentioned ovarian cancer cell lines by Q-PCR.
Our results show that mRNA expression of PR (Figure 3A, panel
a), ERa (Figure 3B, panel a) and ERb (Figure 3C, panel a) appears
higher in cell lines possessing low HYAL1 mRNA expression
(Figure 1C) and vice-versa. In particular, TOV21G and
TOV2444 cell lines have high levels of HYAL1 mRNA expression
and very low mRNA levels of all three receptors (see vertical
arrows in both Figures 1 and 3). Our findings, using a panel of
ovarian cancer cell lines, are concordant with those of breast
cancer cell lines [24].
However, to our knowledge, this inverse relationship between
Hyaluronidase-1 and hormone receptors has not been demon-
strated in tissue samples from cancer patients. Therefore, we
decided to address this issue in the present study. First, we
characterized the level of mRNA expression of all three receptors
(PR, ERa,E R b) in our sample cohort by Q-PCR (Figure 3, b
panels) and we examined the mRNA expression of these receptors
in the publicly available microarray GEO dataset GSE6008
(Figure 3, c panels). Figure 3A shows that PR mRNA expression is
significantly lower (P,0.05) in serous, clear cell and mucinous
ovarian cancers when compared to benign tumors (panel b, our
Q-PCR results) or to normal ovarian tissue (panel c, microarray
results). ERa mRNA expression was also significantly lower
(P,0.05) in clear cell and mucinous tumors although no significant
reduction was observed in the microarray dataset (Figure 3B).
However, ERa expression was significantly higher (P,0.05) in
endometrioid ovarian carcinomas in both datasets (Figure 3B). For
ERb, figure 3C shows that its mRNA expression is significantly
low only in serous epithelial ovarian cancer in both data analyses.
We further went on to verify whether expression of Hyaluron-
idase-1 inversely correlated with that of ERa,E R b and/or PR in
ovarian tumor samples. Spearman correlation coefficients (r) were
calculated to examine a correlation between mRNA expression of
HYAL1 and steroid hormone receptors. Negative correlations were
consistently observed between HYAL1 mRNA expression levels
and those of ERa and PR in clear cell and mucinous ovarian
cancer subtypes (r values for HYAL1 correlation with ERa in clear
cell and mucinous EOCs were respectively 20.461 and 20.310 in
the Q-PCR analysis and 20.595 and 20.467 in the microarray; r
values for HYAL1 correlations with PR in clear cell and mucinous
EOCs were respectively 20.215 and 20.429 in the Q-PCR
analysis and 20.500 and 20.352 in the microarray) (see bold fonts
in Supplemental Table S1). This inverse correlation was
statistically significant for ERa in clear cell and mucinous samples
from the microarray dataset (Figure 4, lower panels, P,0.05). For
the Q-PCR dataset, although no significance was obtained in the
Spearman correlation for HYAL1 and ERa levels in clear cell and
mucinous EOCs, it is noteworthy that tissue samples exhibiting
high HYAL1 levels possess lower ERa expression and vice-versa
(Figure 4, upper panels). Similar results were obtained with HYAL1
and PR correlations in clear cell and mucinous EOCs (Supple-
mental Figure S1). For the other tested samples (Supplemental
Table S1), correlation coefficients were not consistent between the
Q-PCR and the microarray data.
To our knowledge this is the first indication demonstrating a
negative correlation between HYAL1 mRNA expression and ERa
mRNA levels in epithelial ovarian cancer tumors.
Regulation of the HYAL1 gene by the estrogen receptor
alpha in TOV21G cell line
To determine whether HYAL1 gene is under direct regulation
by ERa, we ectopically express ERa in ovarian TOV21G cells
which are derived from clear cell EOC, are negative for ER and
PR (Figure 3) and express high HYAL-1 levels (Figure 1).
Figures 5A and 5B demonstrate that ERa was efficiently expressed
in this cell line showing high mRNA and protein levels after
transient transfection. Functional activity of ERa was confirmed
by a significant activation of known ER target genes [36,37] such
as GREB1 (2.55 fold increase in expression, P,0.01) and pS2/
TFF1 (1.75 fold increase in expression, P,0.05) (Figures 5D and
5E). Using such approach, we observed that expression of ERa in
TOV21G cells induced a 50% decrease in the HYAL1 mRNA
expression compared to mock-transfected cells (P,0.01), indicat-
ing that HYAL1 gene expression is down-regulated by ERa
(Figure 5C).
Discussion
There are more than 190,000 new cases of epithelial ovarian
cancer (EOC) each year worldwide and this malignancy represents
the leading cause of death from gynaecological cancers [1,2]. It is a
complex disease, largely asymptomatic, and over 70% of patients
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20705Figure 3. mRNA Expression of progesterone receptor (A), and estrogen receptors alpha (B) and beta (C) in ovarian cancer cell lines
and tissue samples. i panels) Q-PCR for these receptors was performed on cDNAs from cell lines derived from normal ovarian epithelium, and from
serous, endometrioid, clear cell and mucinous EOCs (see Figure 1C legend for details). Bars represent the mean of the relative mRNA expression for
each receptor normalized to the control gene ERK1. Q-PCR measurements were repeated 3–4 times for each receptor and each cell line. As for Fig. 1,
cell lines derived from different EOC subtypes are represented in separate bars therefore no error bars are represented. Vertical arrows indicate clear
cell and mucinous cell lines having low mRNA expression of these receptors. ii panels) Normalized mRNA expression levels for steroid receptors
determined by Q-PCR on cDNAs from benign tumors, and from serous, endometrioid, clear cell and mucinous EOC tissue samples (see Figure 1A
legend for details). Q-PCR measurements were performed at least three times for each receptor and each tissue sample, and bars represent the mean
6 SEM of the relative mRNA expression for each receptor normalized to the control gene ERK1 in each tissue category. * denotes P,0.05 on Mann
Whitney test. iii panels) Normalized values for hybridization of PR, ERa and ERb probes of the Affymetrix HG_U133A array (see Material and Methods
for details) on RNA samples of normal ovarian tissues, and of serous, endometrioid, clear cell and mucinous EOCs (see Figure 1B legend for details).
Bars represent the mean 6 SEM of the normalized raw values for the expression of each receptor in each tissue category. * denotes P,0.05 on Mann
Whitney test.
doi:10.1371/journal.pone.0020705.g003
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heterogeneous disease, and each EOC subtype exhibits distinct
clinical characteristics, morphology, biological behaviour, and
chemotherapeutic response [3]. Indeed, molecular studies support
the notion that the different histological types likely represent
distinct disease states [54,55]. Nonetheless, it is current practice to
treat all subtypes with the same platinum/taxane chemotherapy,
although some do not respond well to this regimen [56–58]. As a
consequence subtype-specific therapeutic trials have been recom-
mended for clear cell and mucinous EOCs in particular [59]. The
molecular and morphological differences of these EOC subtypes
are also reflected in the efficiency for detection using the only
approved serum biomarker for ovarian cancer, CA125; while 60–
80% of patients with endometrioid and serous EOC show high
levels of serum CA125, only 20–30% of patients with clear cell and
mucinous are positive for this serum biomarker [60]. Therefore,
further genetic and molecular characterizations are needed for
these latter EOC subtypes in order to identify molecules with the
potential to improve early detection.
In the present work, we show that HYAL1 mRNA expression is
elevated in clear cell and mucinous EOC tissue samples, but not in
serous and endometrioid samples, normal ovaries or benign tumors
(Fig. 1). Similar results were obtained by applying two different
techniques on two separate tissue sample cohorts. Concordantly,
HYAL1 mRNA levels and enzymatic activity were elevated in EOC
cell lines derived from clear cell and mucinous subtypes (Fig. 1). No
extensive studies have closely investigated the expression of
HYAL-1 in individual EOC subtypes. Others that have exclusively
examined serous tumours have reported low HYAL1 mRNA
expression levels [16] and unchanged hyaluronidase activities in
tissue extracts [16,17]. Our results showing unchanged levels of
HYAL1 mRNA and plasma activity in serous EOC (Fig. 1) are in
accordance with these latter findings. However, they differ from
those showing low HYAL1 mRNA levels [16]. This discrepancy is
probably related to differences in experimental settings used in each
study regarding quantitative real time RT-PCR. Nevertheless, the
differential expression of HYAL-1 in individual EOC subtypes is
probably related to their distinct molecular characteristics. As
mentioned before, the HYAL1 gene is located in a tumor suppressor
locus at chromosome 3p and cytogenetic studies have revealed
recurrent anomalies of chromosome 3 in ovarian cancer that
include a non-random loss of all or regions of the 3p arm [5,61,62].
However, there are several other candidate tumor suppressor genes
in this region, including SEMA3B and SEMA3F [63,64] as well as
RASSF1 (RAS association domain family 1). In fact, inactivation of
the latter has been implicated in the development of more than 40
types of sporadic human cancers [65,66]. Therefore, it is possible
that the hyaluronidases are not the main tumor suppressor genes in
Figure 4. Inverse correlation of HYAL1 expression with that of estrogen receptor alpha. In upper panels, bars represent relative mRNA
levels of HYAL1 (white bars) and ERa (black bars) measured by Q-PCR for each individual tissue sample. In lower panels, points represent relative
mRNA expression values for each tissue sample from the microarray dataset (GSE6008). Left panels are correlations for clear cell tissue samples and
right panels for mucinous tissue samples. Significance (P,0.05) was analysed by the Spearman correlation coefficient.
doi:10.1371/journal.pone.0020705.g004
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mechanisms in some tumor types. These events are certainly more
frequent in serous EOC which presents higher frequency of
chromosomal instability than the other subtypes [3,67]. The
concept of hyaluronidases as tumor suppressors seems appealing,
as there is a vast literature demonstrating the role of its substrate,
hyaluronan, in tumor progression, survival and metastasis
[19,68,69]. However, the roles of hyaluronidases as tumor pro-
moters have also been extensively reported [22,70]. These studies
showed that up-regulation of hyaluronidases can promote cell cycle
activation, induce extracellular matrix degradation and forma-
tion of angiogenic hyaluronan fragments, and are associated with
tumor growth, invasion, and recurrence in several cancer
types [22,70].
Our current results are in favour of these latter reports. It is
possible that elevated HYAL-1 levels would also have a tumor
promoter role in clear cell and mucinous EOCs, and future
functional studies are warranted to test this interesting possibility.
Significantly, we showed that HYAL-1 activity is particularly high
in the plasma of patients with clear cell EOC (Fig. 2). This was the
first evidence showing high circulating HYAL-1 levels in ovarian
cancer. It has long been known that HYAL-1 is present in
biological fluids such as plasma and urine [44,71]. Interestingly,
levels of hyaluronan and HYAL-1 are reported to be elevated in
urine of patients with bladder cancers [21,22] and HYAL-1 has
been shown to be secreted to the culture medium by some bladder
and prostate cancer cell lines [26,27]. Furthermore, patients with
head and neck carcinomas are shown to have elevated
hyaluronidase activity in their saliva [20]. Our results show that
HYAL-1 is also secreted by the ovarian cancer cell line originating
from the clear cell carcinoma, but not from that of serous EOC
(Fig. 2). Although several molecular markers for EOC have been
identified [3,60,67,72,73], CA125 remains the only clinically
approved serum biomarker for the detection of this disease.
However, as above mentioned, clear cell and mucinous EOCs are
rarely detected by this assay. One interesting perspective would be
to determine the efficacy and feasibility of a combined test to
measure HYAL-1 plasma activity in conjunction with CA125
measurements for ovarian cancer screening.
Previous reports have shown that increased expression of
hyaluronan and HYAL-1 were associated with high grade bladder
and prostate cancers [21,22]. However, in the present work,
significant correlation between HYAL1 mRNA levels and tumor
grade or stage was not obtained for any EOC subtype. It is
possible that HYAL1 levels are associated with parameters other
than disease grade or stage in clear cell and mucinous EOC. Our
results rather indicate that HYAL-1 expression in EOC might
reflect the intrinsic phenotypic characteristics of the distinct
histological subtypes.
EOC is significantly more prevalent and severe in post-
menopausal women. Throughout menopause, changes in the
hormonal milieu ostensibly provide important regulatory switches
for ovarian tumor progression. These changes include elevated
levels of luteinizing hormone (LH) and follicular-stimulating
hormone (FSH), and reduced levels of estrogen and progesterone.
Accordingly, status of gonadotropin and steroid hormone
receptors has been associated with ovarian cancer patients’
survival [49–53,74–76]. FSH and LH receptors are positively
correlated with tumor progression and poor prognosis [74–76], as
well absence of ER and PR has been associated with reduced
survival and poor prognosis [49–53]. Interestingly, different EOC
subtypes have distinct patterns of expression for specific steroid
hormone receptors. We and others have shown that endome-
trioid EOCs are generally ER positive whereas clear cells are
negative ([77] and Fig. 3). It is believed that this characteristic
might account for the less aggressive phenotype of the
endometrioid subtype [3]. Absence of ER in breast cancer has
been consistently associated with tumor progression, recurrence
and metastasis, and despite major advances in surgery and
adjuvant therapies, ER-negative breast cancer remains difficult to
treat [52,78]. Interestingly, ER-negative breast cancer cell lines
have higher hyaluronidase levels than ER-positive cells [24] and
silencing of HYAL1 by RNA interference inhibited cell prolifer-
ation and induced cell cycle arrest in some breast cancer cell lines
[79]. Results from the present work demonstrate that ovarian
cancer cell lines expressing high HYAL-1 levels, e.g. derived from
clear cell and mucinous EOCs (Fig. 1), have low mRNA
expression of ERa,E R b and PR (Fig. 3). More importantly, we
determined that HYAL1 mRNA levels are inversely correlated
with those of ERa specifically in clear cell and mucinous EOC
Figure 5. Ectopic expression of estrogen receptor alpha (ERa)
negatively regulates HYAL1 expression in TOV21G cell line.
Plasmid containing the cDNA sequence of human ERa (named pERa)
was transiently transfected in clear cell ovarian cancer cell line (TOV21G)
and expression efficiency was analysed by immunoblotting (A) and
Q-PCR (B). mRNA levels of HYAL1 (C), GREB1 (D) and TFF1 (E) were also
analysed by Q-PCR in these transfected cell lines. (2) denotes control
cells transfected with empty plasmid, and (+) denotes pERa transfected
cells. In A, immunoblotting was performed using anti-ERa antibody and
the anti-bActin antibody was used as control.
doi:10.1371/journal.pone.0020705.g005
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HYAL1 gene expression in ovarian cancer. Previous studies have
shown that CD44-hyaluronan interaction engages a cascade of
signalling events to promote ERa activation in a serous ovarian
cancer cell line [80]. However, to our knowledge this is the first
demonstration of a correlation between HYAL1 and ERa mRNA
levels in ovarian tumor cells and more importantly in tumor
samples collected from patients. Consistent with such regulation,
we demonstrate that ectopic expression of ERa in a clear cell
EOC cell line (negative for this ER receptor) induced a significant
decrease in HYAL1 gene expression (Fig. 5), which identifies
HYAL1 as an ER target for gene repression. We therefore
postulate that regulation of HYAL1 expression by ERa partici-
pates in ovarian cancer progression. As such HYAL-1 might play
a role in tumor proliferation and cell cycle progression in ER-
negative clear cell and mucinous EOC much in the same way as
has been shown for ER-negative breast cancer [24,79] and for
bladder and prostate cancer cell lines [26,27]. Therefore, it will
be important to further understand the mechanism behind
HYAL1 gene regulation by ERa at the promoter level, and we are
presently working on this subject.
In conclusion, we demonstrate that HYAL-1 is differentially
expressed in morphologically distinct EOC subtypes, and that such
regulation might implicate the estrogen receptor alpha. Our results
also identify Hyaluronidase-1 as a potential target/biomarker for
clear cell and mucinous EOCs and especially in tumors with low
ERa levels.
Supporting Information
Figure S1 Inverse correlation of HYAL1 expression with that of
progesterone receptor. In upper panels, bars represent relative
mRNA levels of HYAL1 (white bars) and PR (shaded bars)
measured by Q-PCR for each individual tissue sample. In lower
panels, points represent relative mRNA expression values for each
tissue sample from the microarray dataset (GSE6008). Left panels
are correlations for clear cell tissue samples and right panels for
mucinous tissue samples.
(TIF)
Table S1 Correlation coefficients for HYAL-1 mRNA expression
with those of progesterone receptor (PR), or estrogen receptors
alpha (ERa) or beta (ERb).
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